Sperginn® Forte

SPERGINN® Forte

SPERGINN® Forte is a dietary supplement containing L-arginine, taurine, vitamin C, vitamin E, coenzyme Q10 and zinc. Zinc contributes to normal fertility and reproduction, as well as maintaining normal testosterone levels in the blood. Vitamin E and C contribute to the protection of cells from oxidative stress. Vitamin C helps reduce fatigue and exhaustion.

SPERGINN® Forte in a product sachet contains active ingredients which contribute, by their synergistic action, to the increase of count, motility and quality of sperm, as well as efficient elimination of erectile dysfunction symptoms.

  • High bioavailability of active substances
  • High absorption of lipophilic active substances
  • Produced with patented technology
  • Complementary therapeutic effect
  • High adherence and compilance of patients
  • Maintenance of high concentration of active component in the body throughout the day

In which conditions is the use of product SPERGINN® Forte?

  • In treatment of male infertility:
    • reduced sperm count, motility or quality
    • after surgical treatment of varicocele
    • as an adjuvant therapy to hormone therapy
  • In the treatment of erectile dysfunction
Male infertility
Erectile dysfunction

Why SPERGINN® Forte?

  • Strong formulation for strengthening of male reproductive health
  • Proven increase of sperm quality, count and motility
  • Contributes to fertility and maintenance of normal testosterone level in the blood
  • Complementary therapy to hormone therapy
  • Protection of cells from oxidative stress
  • Comfortable dosing, one a day

What does SPERGINN® Forte contain?

Active ingredients:
1 sachet
L-arginine
2500 mg
Taurine
500 mg
Vitamin C (L- ascorbic acid)
180 mg
Coenzyme Q10
200 mg
Vitamin E (D-α- tocopheryl acetate)
30 mg
Zinc (zinc-L-pidolate)
1,5 mg
Clinical studies

Method of use

Adults: One sachet a day. Dissolve the content of a sachet in a glass of water (200 ml), stir well and drink.
Notes: Dietary supplements cannot be used as a substitute for a varied and balanced diet. Recommended daily dose must not be exceeded. It does not contain gluten and Iactose.
Package: 12 sachets.

Innventa pharm d.o.o.
Headquarters: No. 36/9 Šumatovačka St., 11000 Belgrade, Serbia
Representative office: No. 3 Trg pobede, 26300 Vršac, Serbia

Social networks

Facebook Instagram Youtube Linkedin

Contact

office@innventa-pharm.com
+381 11 420 44 66

Latest news

Pages

INNventa pharm © 2024. All rights reserved.

MUŠKA NEPLODNOST

Neplodnost ili infertilitet predstavlja nesposobnost seksualno aktivnog para, koji ne koristi kontracepciju tokom jedne godine, da začne potomstvo. Kod 50% parova bez dece, faktor povezan sa muškom neplodnošću usko je povezan sa poremećajem broja, pokretljivosti i izgleda spermatozoida.

Faktori koji utiču na neplodnost kod muškaraca mogu se dovesti u vezu sa urođenim strukturnim poremećajima, stečenim poremećajima mokraćnih kanala i muških polnih organa, prisustvom infekcija, kao i povišenom temperaturom u mošnicama. Na neplodnost kod muškaraca mogu da utiču oboljenja žlezda sa unutrašnjim lučenjem, bolesti imunog sistema, sistemske bolesti vezivnog tkiva, kao i lekovi, toksini, zračenje i stil života. U velikom procentu muške neplodnosti (40-50%) nije moguće utvrditi tačan uzrok koji dovodi do smanjenog broja, loše pokretljivosti, slabijeg kvaliteta spermatozoida i smanjene količine semene tečnosti.

Postavljanje dijagnoze podrazumeva laboratorijsku potvrdu smanjenih vrednosti parametara semene tečnosti, detaljnu hormonsku evaluaciju, mikrobiološka ispitivanja, ultrazvučni pregled i druge metode u cilju otkrivanja uzroka i daljeg terapijskog pristupa.

Lečenje muške neplodnosti sprovodi se, pre svega, u cilju otklanjanja uzroka koji je doveo do razvoja bolesti. U tu svrhu se koriste hormonska terapija, hirurški tretmani kao i potpomognute tehnike oplođenja. Novija naučna istraživanja su pokazala da se korišćenjem klinički dokazanih suplemenata može povećati broj, pokretljivost i kvalitet spermatozoida.

Erektilna disfunkcija

Erektilna disfunkcija predstavlja trajnu nesposobnost postizanja i održavanja erekcije dovoljne za zadovoljavajući seksualni odnos. Erektilna disfunkcija utiče na fizičko i psihosocijalno zdravlje, kao i na kvalitet života obolelog i njegove porodice.

Poremećaj erektilne funkcije može nastati zbog promena na nivou krvnih sudova, nerava, strukture muških polnih organa, hormonske neravnoteže, usled uticaja lekova, zračenja, hirurških procedura ili psiholoških uticaja. Postoje različite kliničke forme poremećaja koje se između ostalog, prema težini, mogu podeliti na laku, srednje tešku ili tešku erektilnu disfunkciju.

Faktori rizika za nastanak erektilne disfunkcije su: nedostatak fizičke aktivnosti, gojaznost, pušenje, povišene koncentracije masnoća u krvi, bolesti bubrega, šećerna bolest i dr. Erektilna disfunkcija i bolesti srca i krvnih sudova imaju zajedničke faktore rizika i često se mogu dijagnostikovati kod istog pacijenta.

Dijagnoza erektilne disfunkcije se bazira na kliničkoj upotrebi validiranih upitnika koji mogu pomoći u proceni težine poremećaja ili efikasnosti terapije (Upitnik IIEF – Internacionalni indeks erektilne funkcije), fizikalnom pregledu, rutinskim ili specifičnim laboratorijskim testovima, hormonskim analizama i dr.
Lečenje erektilne disfunkcije obuhvata, na prvom mestu, utvrđivanje pravog uzroka oboljenja. Za većinu pacijenata neophodna je promena načina života i eliminacija faktora rizika za nastanak poremećaja čime se poboljšava i opšte zdravlje pacijenta. Terapija erektilne disfunkcije obuhvata specifične lekove, hormonska terapiju, kao i druge metode sa ciljem poboljšanja stanja pacijenta, u zavisnosti od samog uzroka oboljevanja. U svrhu lečenja se mogu koristiti i dijetetski suplementi sa dokazanom kliničkom efikasnošću kod poremećaja endotelne funkcije, samostalno ili u kombinaciji sa lekovima.

TERAPIJA L-ARGINOM U DOZI OD 2500 mg I TADALAFIL-om U DOZI OD 5 mg, U KOMBINOVANOJ TERAPIJI I MONOTERAPIJI, U TRETMANU EREKTILNE DISFUNKCIJE10

Dizajn studije: prospektivna, randomizovana, multicentrična studija, 300 pacijenata

Zaključak:

  • L-arginin u dozi od 2500 mg kod blage forme ED je pokazao uporedive terapijske efekte sa tadalafilom u dozi od 5 mg sa manjom incidencom neželjenih efekata
  • L-arginin se pokazao efikasnim u tretmanu srednje teške forme ED
  • Kombinovana terapija (L-arginin i tadalafil) se pokazala superiornom u odnosu na monoterapiju kod pacijenata sa blagom i teškom formom erektilne disfunkcije
  • Minimalna efikasna doza u tretmanu ED iznosi 2500 mg L-arginina, dnevna doza od 1500 mg se nije pokazala efikasnom

*The Daily Therapy With L-Arginine 2,500 mg and Tadalafil 5 mg in Combination and in Monotherapy for the Treatment of Erectile Dysfunction: A Prospective, Randomized Multicentre Study; Gallo L, Pecoraro S, Sarnacchiaro P, Silvani M, Antonini G.

EFEKAT L-ARGININA NA PARAMETRE SEMENE TEČNOSTI U TRETMANU MUŠKOG INFERTILITETA4

Klinička studija je obuhvatila 15 infertilnih pacijenata i kontrolnu grupu od 30 muškaraca sa normalnim fertilitetom

  • Značajno povećanje broja spermatozoida posle tretmana L-argininom (55+7,1 mil/ml) u odnosu na broj pre tretmana (27+2,28 mil/ml)
  • Značajno poboljšanje pokretljivosti i morfologije spermatozoida posle tretmana L-argininom (35+5,89 mil/ml) u komparaciji sa rezultatima na početku studije (15+4,45 mil/ml)
  • Značajno povećanje volumena ejakulata posle tretmana L-argininom (3,15+0,84 ml) u komparaciji sa vrednostima pre početka tretmana (2,2+0,52 ml)
  • Značajno povećanje glutationa i značajna redukcija MDA, IL-6 i CRP u serumu u komparaciji sa vrednostima pre tretmana L-argininom uz značajno povećanje koncentracije testosterona

*The effect of L-Arginine of treatment for infertile men on semen parameters; Abdul Rahman Jihad Manssor1, Zaid Mohammed Mubarak Al–Mahdawi1, Azzawi Mustafa Hadi;

Male infertility

Infertility is the inability of a sexually active, non-contracepting couple to achieve pregnancy in one year. In 50% of childless couples, the factor associated with male infertility is closely related to impaired sperm count, motility and appearance.

Factors that affect infertility in men can be related to congenital structural disorders, acquired disorders of the urinary tract and male genitals, the presence of infections, as well as elevated temperature in the scrotum. Infertility in men can be affected by diseases of the endocrine glands, diseases of the immune system, systemic connective tissue diseases, as well as drugs, toxins, radiation and lifestyle. It is not possible to determine the exact cause that leads to reduced numbers, poor motility, poor sperm quality and reduced semen volume in a large percentage of male infertility (40-50%).

Establishing a diagnosis involves laboratory confirmation of reduced semen parameters, detailed hormone evaluation, microbiological tests, ultrasound examination and other methods in order to discover the cause and further therapeutic approach.

Treatment of male infertility is carried out, primarily, in order to eliminate the cause that led to the development of the disease. Hormone therapy, surgical treatments as well as assisted fertilization techniques are used for this purpose. Recent scientific studies have shown that the use of clinically proven supplements can increase sperm count, motility and quality.

Erectile dysfunction

Erectile dysfunction is a permanent inability to achieve and maintain an erection sufficient for the satisfying sexual intercourse. Erectile dysfunction affects the physical and psychosocial health, as well as the quality of life of the patient and his family.

Erectile dysfunction can develop due to changes in blood vessels, nerves, the structure of the male sexual organs, hormonal imbalance, due to the influence of drugs, radiation, surgical procedures or psychological influences. There are various clinical forms of the disorder which, among other things, can be classified, according to their severity, as mild, moderate or severe erectile dysfunction.

Risk factors for the development of erectile dysfunction are: lack of physical activity, obesity, smoking, elevated blood fat concentrations, kidney disease, diabetes, etc. Erectile dysfunction and cardiovascular disease have common risk factors and can often be diagnosed in the same patient.

Diagnosis of erectile dysfunction is based on the clinical use of validated questionnaires which can help in the assessment of the disorder severity or efficiency of therapy (International Index of Erectile Function – IIEF), physical examination, routine or specific laboratory tests, hormone analyses etc.
Treatment of erectile dysfunction includes, primarily, establishing the true cause of the disease. Change of the lifestyle and elimination of the risk factors for the development of the disorder are necessary for the majority of patients, which improves also the general health of the patient. Treatment of erectile dysfunction includes specific drugs, hormonal therapy, as well as other methods aimed at improving the patient’s condition, depending on the cause of the disease. Dietary supplements with proven clinical efficacy can also be used in the therapy of endothelial function disorders, alone or in combination with drugs.

THERAPY WITH L-ARGININE IN DOSE OF 2500 mg AND TADALAFIL IN DOSE OF 5 mg, IN COMBINED THERAPY AND MONOTHERAPY, IN TREATMENT OF ERECTILE DYSFUNCTION10

Study design: prospective, randomized, multi-centric study, 300 patients.

Conclusion:

  • L-arginine in the dose of 2500 mg in mild form of ED demonstrated comparable therapeutic effects with tadalafil in dose of 5 mg with smaller incidence of adverse effects
  • L-arginine proved to be efficient in treatment of moderate form of ED
  • Combined therapy (L-arginine and tadalafil) proved to be superior compared to monotherapy in patients with mild and moderate form of erectile dysfunction
  • Minimum efficient dose in the treatment of ED amounts to 2500 mg of L-arginine, daily dose of 1500 mg did not prove to be efficient

*The effect of L-Arginine of treatment for infertile men on semen parameters; Abdul Rahman Jihad Manssor1, Zaid Mohammed Mubarak Al–Mahdawi1, Azzawi Mustafa Hadi;

EFFECT OF L-ARGININE ON SEMEN PARAMETERS IN THE TREATMENT OF MALE INFERTILITY3

Clinical study covered 15 infertile patients and control group of 30 men with normal fertility.

  • Significant increase of sperm count after treatment with L-arginine (55±7,1 mil/ml) compared to the count before the treatment (27±2,28 mil/ml)
  • Significant improvement of sperm motility and morphology after treatment with L-arginine (35±5,89 %) compared to the results at the beginning of the study (15±4,45 %)
  • Significant increase in ejaculate volume after treatment with L-arginine (3,15±0,84 ml) compared to the values before the beginning of treatment (2,2±0,52 ml)
  • Significant serum increase in glutathione and significant reduction in MDA, IL-6 and CRP compared to the values before the treatment with L-arginine with significant increase of testosterone concentration

*The Daily Therapy With L-Arginine 2,500 mg and Tadalafil 5 mg in Combination and in Monotherapy for the Treatment of Erectile Dysfunction: A Prospective, Randomized Multicentre Study; Gallo L, Pecoraro S, Sarnacchiaro P, Silvani M, Antonini G.